新天药业
(002873)
| 流通市值：25.78亿 | | | 总市值：26.36亿 |
| 流通股本：2.39亿 | | | 总股本：2.44亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 94,467,566.35 | 99,758,021.83 | 118,164,427.88 | 136,716,254.72 |
| 交易性金融资产 | 95,857.02 | 106,000.62 | 118,680.12 | 104,479.08 |
| 应收票据及应收账款 | 284,243,877.08 | 322,801,080.67 | 316,574,443.06 | 326,523,336.29 |
| 其中：应收票据 | 7,837,288.24 | 3,293,990.28 | 8,130,509.29 | 5,355,336.14 |
| 应收账款 | 276,406,588.84 | 319,507,090.39 | 308,443,933.77 | 321,168,000.15 |
| 应收款项融资 | 6,329,306.3 | 5,908,061.54 | 9,099,792.98 | 8,271,923.82 |
| 预付款项 | 8,100,205.84 | 8,290,338.57 | 5,064,734.15 | 3,385,378.14 |
| 其他应收款合计 | 16,576,671.12 | 18,933,935.73 | 18,695,166.28 | 35,406,813.23 |
| 存货 | 146,199,483.75 | 129,515,012.25 | 145,478,159.62 | 148,974,416.46 |
| 其他流动资产 | 3,984,821.85 | 3,497,035.63 | 3,611,642.74 | 2,802,286.83 |
| 流动资产合计 | 559,997,789.31 | 588,809,486.84 | 616,807,046.83 | 662,184,888.57 |
| 非流动资产: | | | | |
| 其他权益工具投资 | 412,045,700 | 412,045,700 | 412,045,700 | 383,250,542.05 |
| 其他非流动金融资产 | 22,601.7 | 22,601.7 | 22,601.7 | 23,565.39 |
| 投资性房地产 | 4,364,152.04 | 3,387,025.67 | 3,410,601.8 | 3,434,177.93 |
| 固定资产 | 628,841,022.29 | 635,260,393.91 | 640,849,300.08 | 651,030,699.88 |
| 在建工程 | 53,138,091.6 | 56,628,306.76 | 55,805,572.21 | 55,330,170.26 |
| 使用权资产 | 11,301,709.66 | 12,604,283.56 | 12,178,391.18 | 13,569,072.47 |
| 无形资产 | 106,663,136.44 | 107,419,702.53 | 108,956,978.16 | 81,050,532.65 |
| 开发支出 | 87,751,035 | 86,119,179.82 | 85,051,284.9 | 96,964,557.76 |
| 长期待摊费用 | 9,557,320.12 | 4,906,638.34 | 5,309,973.85 | 5,713,309.35 |
| 递延所得税资产 | 10,297,126.76 | 10,294,279.67 | 10,063,869.78 | 10,938,648.66 |
| 非流动资产合计 | 1,323,981,895.61 | 1,328,688,111.96 | 1,333,694,273.66 | 1,301,305,276.4 |
| 资产总计 | 1,883,979,684.92 | 1,917,497,598.8 | 1,950,501,320.49 | 1,963,490,164.97 |
| 流动负债: | | | | |
| 短期借款 | 71,063,276.26 | 121,134,180.55 | 306,242,291.69 | 452,000,000 |
| 应付票据及应付账款 | 82,295,885.11 | 65,161,887 | 83,364,787.96 | 72,232,915.48 |
| 应付账款 | 82,295,885.11 | 65,161,887 | 83,364,787.96 | 72,232,915.48 |
| 预收款项 | 66,165.41 | - | - | - |
| 合同负债 | 438,271.04 | 552,281.85 | 521,248.65 | 543,969.8 |
| 应付职工薪酬 | 13,752,141.23 | 13,708,574.87 | 15,284,060.37 | 14,081,322.98 |
| 应交税费 | 14,375,655.81 | 21,483,296 | 19,343,213.65 | 25,945,024.44 |
| 其他应付款合计 | 16,723,913.28 | 17,466,744.91 | 30,382,803.41 | 11,232,559.78 |
| 应付股利 | - | - | 9,411,911.04 | - |
| 一年内到期的非流动负债 | 10,934,705.34 | 32,359,710.69 | 25,772,552.07 | 32,426,428.58 |
| 其他流动负债 | 1,520,381.27 | 1,054,858.99 | 468,042.32 | 70,716.07 |
| 流动负债合计 | 211,170,394.75 | 272,921,534.86 | 481,379,000.12 | 608,532,937.13 |
| 非流动负债: | | | | |
| 长期借款 | 432,950,000 | 391,880,000 | 221,400,000 | 109,950,000 |
| 应付债券 | - | - | - | 148,888,628.75 |
| 租赁负债 | 7,140,300.1 | 7,754,827.65 | 6,769,206.83 | 7,836,670.8 |
| 长期应付款 | 531,811.22 | 532,000.98 | 550,240.98 | 562,699.98 |
| 递延收益 | 23,766,265.94 | 23,444,318.41 | 23,581,819.75 | 23,485,894.53 |
| 递延所得税负债 | 22,056,853.42 | 22,061,614.75 | 22,105,205.11 | 17,575,479.47 |
| 非流动负债合计 | 486,445,230.68 | 445,672,761.79 | 274,406,472.67 | 308,299,373.53 |
| 负债合计 | 697,615,625.43 | 718,594,296.65 | 755,785,472.79 | 916,832,310.66 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 244,103,806 | 244,103,806 | 244,103,806 | 229,450,267 |
| 其他权益工具 | - | - | - | 20,224,631.23 |
| 资本公积 | 282,352,942.7 | 282,352,942.7 | 282,352,942.7 | 173,519,274.15 |
| 减:库存股 | 75,303,968.97 | 75,303,968.97 | 75,303,968.97 | 113,712,296.91 |
| 其他综合收益 | 78,238,845 | 78,238,845 | 78,238,845 | 53,762,960.74 |
| 盈余公积 | 101,927,921.67 | 101,927,921.67 | 101,927,921.67 | 94,013,806.78 |
| 未分配利润 | 555,044,513.09 | 567,583,755.75 | 563,396,301.3 | 589,399,211.32 |
| 归属于母公司股东权益合计 | 1,186,364,059.49 | 1,198,903,302.15 | 1,194,715,847.7 | 1,046,657,854.31 |
| 股东权益合计 | 1,186,364,059.49 | 1,198,903,302.15 | 1,194,715,847.7 | 1,046,657,854.31 |
| 负债和股东权益合计 | 1,883,979,684.92 | 1,917,497,598.8 | 1,950,501,320.49 | 1,963,490,164.97 |
| 公告日期 | 2025-07-31 | 2025-04-25 | 2025-04-25 | 2024-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |